BAY 38-7271 is selective and highly potent and cannabinoidCB₁/CB₂receptoragonist, withK_is of 1.85 nM and 5.96 nM for recombinant human CB₁receptor and CB₂receptor, respectively. BAY 38-7271 has strong neuroprotective properties^[1].

BAY 38-7271 shows only minor interactions at the micromolar range with other binding sites such as adenosine A₃receptor (IC₅₀= 7.5 μM), peripheral GABA_Abenzodiazepine receptor (IC₅₀= 971 nM), melatonin ML₁receptor (IC₅₀= 3.3 μM), and at the monoamine transporter (IC₅₀= 1.7 μM)^[1].

BAY 38-7271 (Ed₅₀= 0.02 mg/kg; i.v. and 0.5 mg/kg; i.p.) induces a potent and dose-de-pendent reduction in core body temperature^[1].
BAY 38-7271 has low physical dependence liability and is not essentially different from that of other cannabinoid CB₁receptor agonists^[1].
BAY 38-7271 (1-1000 ng/kg/h; i.v. infusion; for 4 hours) shows neuroprotective efficacy in the rat SDH model^[1].
BAY 38-7271 also has neuroprotective efficacy in models of transient and permanent occlusion of the middle cerebral artery and brain edema models^[1].

430.44

C₂₀H₂₁F₃O₅S

212188-60-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.